Early management of patients with acute heart failure: State of the art and future directions - A consensus document from the SAEM/HFSA acute heart failure working group

Academic Emergency Medicine

Volumn 22, Issue 1, 2015, Pages 94-112

  Collins, Sean P ^a   Storrow, Alan B ^a   Levy, Phillip D ^b   Albert, Nancy ⁱ   Butler, Javed ^j   Ezekowitz, Justin A ^k   Michael Felker, G ^l   Fermann, Gregory J ^c   Fonarow, Gregg C ^m   Givertz, Michael M ^d   Hiestand, Brian ^e   Hollander, Judd E ^f   Lanfear, David E ⁿ   Pang, Peter S ^g   Frank Peacock, W ^h   Sawyer, Douglas B ^a   Teerlink, John R ^o   Lenihan, Daniel J ^a  

^a VANDERBILT UNIVERSITY   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e WAKE FOREST SCHOOL OF MEDICINE   (United States)

^f THOMAS JEFFERSON UNIVERSITY   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h BAYLOR COLLEGE OF MEDICINE   (United States)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

^j EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^k UNIVERSITY OF ALBERTA   (Canada)

^l DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^m UCLA MEDICAL CENTER   (United States)

ⁿ WAYNE STATE UNIVERSITY   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; BIOLOGICAL MARKER;

ACUTE HEART FAILURE; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL (TOPIC); ECHOGRAPHY; ELECTROCARDIOGRAM; EMERGENCY PHYSICIAN; EMERGENCY WARD; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; IMPEDANCE CARDIOGRAPHY; MEDICAL HISTORY; OBSERVATION UNIT; PATIENT DECISION MAKING; PHYSICAL EXAMINATION; POINT OF CARE TESTING; PRACTICE GUIDELINE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; ACUTE DISEASE; CONSENSUS; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; EMERGENCY HEALTH SERVICE; HEART FAILURE; ORGANIZATION AND MANAGEMENT; RISK ASSESSMENT;

ACUTE DISEASE; BIOMARKERS; CLINICAL TRIALS AS TOPIC; CONSENSUS; DISEASE MANAGEMENT; ELECTROCARDIOGRAPHY; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; PATIENT DISCHARGE; PHYSICAL EXAMINATION; RADIOGRAPHY, THORACIC; RISK ASSESSMENT;

EID: 84920861658     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/acem.12538     Document Type: Article

References (161)

1. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011; 123: e18-e209.
2. Storrow AB, Jenkins CA, Self WH, et al. The burden of acute heart failure on U.S. emergency departments. JACC. Heart Fail 2014; 2: 269-77.
3. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 2014; 129: e28-e292.
4. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 2011; 123: 933-44.
5. Peacock WF, Emerman C, Costanzo MR, Diercks DB, Lopatin M, Fonarow GC,. Early vasoactive drugs improve heart failure outcomes. Congest Heart Fail 2009; 15: 256-64.
6. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008; 52: 534-40.
7. Brar S, McAlister FA, Youngson E, Rowe BH,. Do outcomes for patients with heart failure vary by emergency department volume? Circ Heart Fail 2013; 6: 1147-54.
8. Rame JE, Sheffield MA, Dries DL, et al. Outcomes after emergency department discharge with a primary diagnosis of heart failure. Am Heart J 2001; 142: 714-9.
9. Singer AJ, Birkhahn RH, Guss D, et al. Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): a randomized controlled trial of the effect of serial B-type natriuretic peptide testing on patient management. Circ Heart Fail 2009; 2: 287-93.
10. Hsieh M, Auble TE, Yealy DM,. Validation of the Acute Heart Failure Index. Ann Emerg Med 2008; 51: 37-44.
11. Mueller C, Laule-Kilian K, Schindler C, et al. Cost-effectiveness of B-type natriuretic peptide testing in patients with acute dyspnea. Arch Intern Med 2006; 166: 1081-7.
12. Collins S, Storrow AB, Kirk JD, Pang PS, Diercks DB, Gheorghiade M,. Beyond pulmonary edema: diagnostic, risk stratification, and treatment challenges of acute heart failure management in the emergency department. Ann Emerg Med 2008; 51: 45-57.
13. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT,. Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 2005; 294: 1944-56.
14. Wong GC, Ayas NT,. Clinical approaches to the diagnosis of acute heart failure. Curr Opin Cardiol 2007; 22: 207-13.
15. Drazner MH, Rame JE, Stevenson LW, Dries DL,. Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 2001; 345: 574-81.
16. Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW,. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999; 18: 1126-32.
17. Collins SP, Lindsell CJ, Peacock WF, et al. The combined utility of an S3 heart sound and B-type natriuretic peptide levels in emergency department patients with dyspnea. J Card Fail 2006; 12: 286-92.
18. Collins SP, Lindsell CJ, Peacock WF, Hedger VD, Storrow AB,. The effect of treatment on the presence of abnormal heart sounds in emergency department patients with heart failure. Am J Emerg Med 2005; 24: 25-32.
19. Collins SP, Lindsell CJ, Storrow AB, Abraham WT,. Prevalence of negative chest radiography results in the emergency department patient with decompensated heart failure. Ann Emerg Med 2006; 47: 13-8.
20. Volpicelli G, Caramello V, Cardinale L, Mussa A, Bar F, Frascisco MF,. Bedside ultrasound of the lung for the monitoring of acute decompensated heart failure. Am J Emerg Med 2008; 26: 585-91.
21. Chakko S, Woska D, Martinez H, et al. Clinical, radiographic, and hemodynamic correlations in chronic congestive heart failure: conflicting results may lead to inappropriate care. Am J Med 1991; 90: 353-9.
22. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347: 161-7.
23. McCullough PA, Hollander JE, Nowak RM, et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med 2003; 10: 198-204.
24. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M,. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135: 825-32.
25. Lindenfeld J, Albert NM, Boehmer JP, et al. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010; 16: e1-194.
26. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147-239.
27. Karayannis G, Triposkiadis F, Skoularigis J, Georgoulias P, Butler J, Giamouzis G,. The emerging role of Galectin-3 and ST2 in heart failure: practical considerations and pitfalls using novel biomarkers. Curr Heart Fail Rep 2013; 10: 441-9.
28. Shah RV, Chen-Tournoux AA, Picard MH, van Kimmenade RR, Januzzi JL,. Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. Eur J Heart Fail 2010; 12: 826-32.
29. Maisel AS, Clopton P, Krishnaswamy P, et al. Impact of age, race, and sex on the ability of B-type natriuretic peptide to aid in the emergency diagnosis of heart failure: results from the Breathing Not Properly (BNP) multinational study. Am Heart J 2004; 147: 1078-84.
30. Pasha SM, Klok FA, van der Bijl N, de Roos A, Kroft LJ, Huisman MV,. NT-pro-BNP levels in patients with acute pulmonary embolism are correlated to right but not left ventricular volume and function. Thromb Haemost 2012; 108: 367-72.
31. Luchner A, Hengstenberg C, Lowel H, Riegger GA, Schunkert H, Holmer S,. Effect of compensated renal dysfunction on approved heart failure markers: direct comparison of brain natriuretic peptide (BNP) and N-terminal pro-BNP. Hypertension 2005; 46: 118-23.
32. Cavagna L, Caporali R, Klersy C, et al. Comparison of brain natriuretic peptide (BNP) and NT-proBNP in screening for pulmonary arterial hypertension in patients with systemic sclerosis. J Rheumatol 2010; 37: 2064-70.
33. Jorge AJ, Freire MD, Ribeiro ML, et al. [Utility of B-type natriuretic peptide measurement in outpatients with heart failure with preserved ejection fraction] (in Portuguese). Rev Port Cardiol 2013; 32: 647-52.
34. Wang TJ, Larson MG, Levy D, et al. Heritability and genetic linkage of plasma natriuretic peptide levels. Circulation 2003; 108: 13-6.
35. Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, et al. The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. Mayo Clin Proc 2011; 86: 210-8.
36. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail 2008; 10: 824-39.
37. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106: 416-22.
38. Carr BG, Dean AJ, Everett WW, et al. Intensivist bedside ultrasound (INBU) for volume assessment in the intensive care unit: a pilot study. J Trauma 2007; 63: 495-500.
39. Kimura BJ, Dalugdugan R, Gilcrease GW 3rd, Phan JN, Showalter BK, Wolfson T,. The effect of breathing manner on inferior vena caval diameter. Eur J Echocardiog 2011; 12: 120-3.
40. Dean A, Stahmer S,. Ultrasonography and emergency cardiac care. in:, Field JM, ed. The Textbook of Emergency Cardiovascular Care and CPR. New York, NY: Wolters Kluwer, 2009: 129-48.
41. Agricola E, Bove T, Oppizzi M, et al. "Ultrasound comet-tail images": a marker of pulmonary edema: a comparative study with wedge pressure and extravascular lung water. Chest 2005; 127: 1690-5.
42. Liteplo AS, Marill KA, Villen T, et al. Emergency thoracic ultrasound in the differentiation of the etiology of shortness of breath (ETUDES): sonographic B-lines and N-terminal pro-brain-type natriuretic peptide in diagnosing congestive heart failure. Acad Emerg Med 2009; 16: 201-10.
43. Lichtenstein DA, Meziere GA,. Relevance of lung ultrasound in the diagnosis of acute respiratory failure: the BLUE protocol. Chest 2008; 134: 117-25.
44. Volpicelli G, Mussa A, Garofalo G, et al. Bedside lung ultrasound in the assessment of alveolar-interstitial syndrome. Am J Emerg Med 2006; 24: 689-96.
45. Lichtenstein D, Goldstein I, Mourgeon E, Cluzel P, Grenier P, Rouby JJ,. Comparative diagnostic performances of auscultation, chest radiography, and lung ultrasonography in acute respiratory distress syndrome. Anesthesiology 2004; 100: 9-15.
46. Maines M, Catanzariti D, Angheben C, Valsecchi S, Comisso J, Vergara G,. Intrathoracic impedance and ultrasound lung comets in heart failure deterioration monitoring. Pacing Clin Electrophysiol 2011; 34: 968-74.
47. Mullens W,. Oliveira LP, Verga T, Wilkoff BL, Wilson Tang WH. Insights from internet-based remote intrathoracic impedance monitoring as part of a heart failure disease management program. Congest Heart Fail 2010; 16: 159-63.
48. Shochat M, Charach G, Meyler S, et al. Internal thoracic impedance monitoring: a novel method for the preclinical detection of acute heart failure. Cardiovasc Revasc Med 2006; 7: 41-5.
49. Hirschl MM, Kittler H, Woisetschlager C, et al. Simultaneous comparison of thoracic bioimpedance and arterial pulse waveform-derived cardiac output with thermodilution measurement. Crit Care Med 2000; 28: 1798-802.
50. Piccoli A, Codognotto M, Cianci V, et al. Differentiation of cardiac and noncardiac dyspnea using bioelectrical impedance vector analysis (BIVA). J Card Fail 2012; 18: 226-32.
51. Schlendorf KH, Russell SD,. New diagnostic devices in heart failure. Curr Opin Cardiol 2010; 25: 262-7.
52. Neuenschwander JF, Hiestand BC, Peacock WF, et al. A pilot study of implantable cardiac device interrogation by emergency department personnel. Crit Pathways Cardiol 2014; 13: 6-8.
53. Nowak RM, DiSomma S, Nanayakkara P, et al. The noninvasive hemodynamic phenotyping of patients presenting to the emergency department with acute heart failure: prognostic and therapeutic implications [abstract]. Acad Emerg Med 2014; 21: S269-70.
54. Givertz MM, Teerlink JR, Albert NM, et al. Acute decompensated heart failure: update on new and emerging evidence and directions for future research. J Card Fail 2013; 19: 371-89.
55. Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364: 797-805.
56. Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013; 381: 29-39.
57. Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367: 2296-304.
58. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14: 803-69.
59. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J,. Noninvasive ventilation in acute cardiogenic pulmonary edema. N Engl J Med 2008; 359: 142-51.
60. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011; 365: 32-43.
61. Ramirez A, Abelmann WH,. Cardiac decompensation. N Engl J Med 1974; 290: 499-501.
62. Gheorghiade M, Braunwald E,. A proposed model for initial assessment and management of acute heart failure syndromes. JAMA 2011; 305: 1702-3.
63. Peacock WF, Chandra A, Char D, et al. Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO). Am Heart J 2014; 167: 529-36.
64. Cotter G, Felker GM, Adams KF, Milo-Cotter O, O'Connor CM,. The pathophysiology of acute heart failure-is it all about fluid accumulation? Am Heart J 2008; 155: 9-18.
65. Cotter G, Metra M, Milo-Cotter O, Dittrich HC, Gheorghiade M,. Fluid overload in acute heart failure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008; 10: 165-9.
66. Levy P, Compton S, Welch R, et al. Treatment of severe decompensated heart failure with high-dose intravenous nitroglycerin: a feasibility and outcome analysis. Ann Emerg Med 2007; 50: 144-52.
67. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet 1998; 351: 389-93.
68. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006; 296: 2217-26.
69. Adams KF Jr, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005; 149: 209-16.
70. Fallick C, Sobotka PA, Dunlap ME,. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail 2011; 4: 669-75.
71. Setoguchi S, Stevenson LW, Schneeweiss S,. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007; 154: 260-6.
72. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007; 116: 1482-7.
73. Cuffe MS, Califf RM, Adams KF Jr, et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002; 287: 1541-7.
74. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-31.
75. Gheorghiade M, Gattis WA, O'Connor CM, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004; 291: 1963-71.
76. Mebazaa A, Nieminen MS, Packer M, et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007; 297: 1883-91.
77. Gheorghiade M, Bohm M, Greene SJ, et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-35.
78. Massie BM, O'Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-28.
79. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007; 298: 2009-19.
80. Wakai A, McCabe A, Kidney R, et al. Nitrates for acute heart failure syndromes. Cochrane Database Syst Rev 2013; 8: CD005151.
81. Chen HH, Anstrom KJ, Givertz MM, et al. Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013; 18 (310): 2533-43.
82. Schuur JD, Venkatesh AK,. The growing role of emergency departments in hospital admissions. N Engl J Med 2012; 367: 391-3.
83. National Center for Health Statistics. Health, United States, 2012: With Special Feature on Emergency Care. Hyattsville, MD: U.S. Government Printing Office, 2013.
84. McCausland JB, Machi MS, Yealy DM,. Emergency physicians' risk attitudes in acute decompensated heart failure patients. Acad Emerg Med 2010; 17: 108-10.
85. Collins SP, Storrow AB,. Moving toward comprehensive acute heart failure risk assessment in the emergency department: the importance of self-care and shared decision making. JACC Heart Fail 2013; 1: 273-80.
86. Ezekowitz JA, Bakal JA, Kaul P, Westerhout CM, Armstrong PW,. Acute heart failure in the emergency department: short and long-term outcomes of elderly patients with heart failure. Eur J Heart Fail 2008; 10: 308-14.
87. Lee DS, Schull MJ, Alter DA, et al. Early deaths in patients with heart failure discharged from the emergency department: a population-based analysis. Circ Heart Fail 2010; 3: 228-35.
88. Lee DS, Stitt A, Austin PC, et al. Prediction of heart failure mortality in emergent care: a cohort study. Ann Intern Med 2012; 156: 767-75.
89. Pang PS, Jesse R, Collins SP, Maisel A,. Patients with acute heart failure in the emergency department: do they all need to be admitted? J Card Fail 2012; 18: 900-3.
90. Weintraub NL, Collins SP, Pang PS, et al. Acute heart failure syndromes: emergency department presentation, treatment, and disposition: current approaches and future aims: a scientific statement from the American Heart Association. Circulation 2010; 122: 1975-96.
91. Peacock WF 4th, De Marco T, Fonarow GC, et al. Cardiac troponin and outcome in acute heart failure. N Engl J Med 2008; 358: 2117-26.
92. Collins SP, Lindsell CJ, Jenkins CA, et al. Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies. Am Heart J 2012; 164: 825-34.
93. Collins SP, Storrow AB,. Acute heart failure risk stratification: can we define low risk? Heart Fail Clin 2009; 5: 75-83, vii.
94. Butler J, Hanumanthu S, Chomsky D, Wilson JR,. Frequency of low-risk hospital admissions for heart failure. Am J Cardiol 1998; 81: 41-4.
95. Collins SP, Lindsell CJ, Naftilan AJ, et al. Low-risk acute heart failure patients: external validation of the Society of Chest Pain Center's recommendations. Crit Pathw Cardiol 2009; 8: 99-103.
96. Collins SP, Peacock WF, Lindsell CJ, et al. S3 detection as a diagnostic and prognostic aid in emergency department patients with acute dyspnea. Ann Emerg Med 2009; 53: 748-57.
97. Diercks DB, Peacock WF, Kirk JD, Weber JE,. ED patients with heart failure: identification of an observational unit-appropriate cohort. Am J Emerg Med 2006; 24: 319-24.
98. Peacock WF, Fonarow GC, Ander DS, et al. Society of Chest Pain Centers Recommendations for the evaluation and management of the observation stay acute heart failure patient: a report from the Society of Chest Pain Centers Acute Heart Failure Committee. Critical Pathw Cardiol 2008; 7: 83-6.
99. Auble TE, Hsieh M, Gardner W, et al. A prediction rule to identify low-risk patients with heart failure. Acad Emerg Med 2005; 12: 514-21.
100. Auble TE, Hsieh M, McCausland JB, Yealy DM,. Comparison of four clinical prediction rules for estimating risk in heart failure. Ann Emerg Med 2007; 50: 127-35.
101. Metra M, Cotter G, Davison BA, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 2013; 61: 196-206.
102. McKesson Corp. InterQual Actionable Evidence-Based Criteria Portfolio. Available at: http://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCAQFjAA&url=http%3A%2F%2Fwww.mckesson.com%2Fdocuments%2Fpayers%2Finterqual-criteria%2F&ei=s-MuVLTeKI3saMjbgtAG&usg=AFQjCNFDpQwjPYF5o74M4k40OBcH-1pTmw&sig2 = wDNIMquhHsV-X45-902SsQ&bvm=bv.76802529,d.d2s&cad=rja. Acce-ssed Oct 3, 2014.
103. MCG Health, LLC. Indicia for Utilization Review. Available at: http://www.careguidelines.com/. Accessed Oct 3, 2014.
104. Wang H, Robinson RD, Coppola M, et al. The accuracy of interqual criteria in determining the need for observation versus hospitalization in emergency department patients with chronic heart failure. Critical Pathw Cardiol 2013; 12: 192-6.
105. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010; 303: 1716-22.
106. Lee DS, Stukel TA, Austin PC, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation 2010; 122: 1806-14.
107. Takeda A, Taylor SJ, Taylor RS, Khan F, Krum H, Underwood M,. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2012; 9: CD002752.
108. Wu JR, Moser DK, Lennie TA, Burkhart PV,. Medication adherence in patients who have heart failure: a review of the literature. Nurs Clin North Am 2008; 43: 133-53; vii-viii.
109. van der Wal MH, Jaarsma T,. Adherence in heart failure in the elderly: problem and possible solutions. Int J Cardiol 2008; 125: 203-8.
110. Jovicic A, Holroyd-Leduc JM, Straus SE,. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovas Disorders 2006; 6: 43.
111. Barnason S, Zimmerman L, Young L,. An integrative review of interventions promoting self-care of patients with heart failure. J Clin Nurs 2012; 21: 448-75.
112. McAlister FA, Stewart S, Ferrua S, McMurray JJ,. Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. J Am Coll Cardiol 2004; 44: 810-9.
113. Riegel B, Carlson B,. Facilitators and barriers to heart failure self-care. Patient Educ Couns 2002; 46: 287-95.
114. Riegel B, Moser DK, Anker SD, et al. State of the science: promoting self-care in persons with heart failure: a scientific statement from the American Heart Association. Circulation 2009; 120: 1141-63.
115. Fonarow GC, Stough WG, Abraham WT, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J Am Coll Cardiol 2007; 50: 768-77.
116. Yancy CW, Lopatin M, Stevenson LW, De Marco T, Fonarow GC,. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006; 47: 76-84.
117. Sheehy AM, Graf B, Gangireddy S, et al. Hospitalized but not admitted: characteristics of patients with "observation status" at an academic medical center. JAMA Intern Med 2013; 173: 1991-8.
118. Wiler JL, Ross MA, Ginde AA,. National study of emergency department observation services. Acad Emerg Med 2011; 18: 959-65.
119. Somekh NN, Rachko M, Husk G, Friedmann P, Bergmann SR,. Differences in diagnostic evaluation and clinical outcomes in the care of patients with chest pain based on admitting service: the benefits of a dedicated chest pain unit. J Nucl Cardiol 2008; 15: 186-92.
120. Leykum LK, Huerta V, Mortensen E,. Implementation of a hospitalist-run observation unit and impact on length of stay (LOS): a brief report. J Hosp Med 2010; 5: E2-5.
121. Lucas BP, Kumapley R, Mba B, et al. A hospitalist-run short-stay unit: features that predict length-of-stay and eventual admission to traditional inpatient services. J Hosp Med 2009; 4: 276-84.
122. Schrager J, Wheatley M, Georgiopoulou V, et al. Favorable bed utilization and readmission rates for emergency department observation unit heart failure patients. Acad Emerg Med 2013; 20: 554-61.
123. Storrow AB, Collins SP, Lyons MS, Wagoner LE, Gibler WB, Lindsell CJ,. Emergency department observation of heart failure: preliminary analysis of safety and cost. Congest Heart Fail 2005; 11: 68-72.
124. Peacock WF, Fonarow GC, Ander DS, et al. Society of Chest Pain Centers recommendations for the evaluation and management of the observation stay acute heart failure patient-parts 1-6. Acute Card Care 2009; 11: 3-42.
125. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-39.
126. Ezekowitz JA, Hernandez AF, O'Connor CM, et al. Assessment of dyspnea in acute decompensated heart failure: insights from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) on the contributions of peak expiratory flow. J Am Coll Cardiol 2012; 59: 1441-8.
127. Pang PS, Konstam MA, Krasa HB, et al. Effects of tolvaptan on dyspnoea relief from the EVEREST trials. Eur Heart J 2009; 30: 2233-40.
128. Metra M, O'Connor CM, Davison BA, et al. Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study. Eur Heart J 2011; 32: 1519-34.
129. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail 2010; 12: 1130-9.
130. Pang PS, Cleland JG, Teerlink JR, et al. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach. Eur Heart J 2008; 29: 816-24.
131. Redfield M, Butler J, O'Connor C M, et al. Reliable Evaluation of Dyspnea in the ROSE AHF trial (RED ROSE). J Am Coll Cardioll 2014; 63 (12 Suppl): doi: 10.1016/S0735-1097(14)60751-8.
132. Afilalo J, Alexander KP, Mack MJ, et al. Frailty assessment in the cardiovascular care of older adults. J Am Coll Cardiol 2014; 63: 747-62.
133. Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet 2011; 377: 658-66.
134. Sharma GV, Woods PA, Lindsey N, et al. Noninvasive monitoring of left ventricular end-diastolic pressure reduces rehospitalization rates in patients hospitalized for heart failure: a randomized controlled trial. J Card Fail 2011; 17: 718-25.
135. Maisel A, Hollander JE, Guss D, et al. Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 2004; 44: 1328-33.
136. McCullough PA, Duc P, Omland T, et al. B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study. Am J Kidney Dis 2003; 41: 571-9.
137. Sanford SD, Lichstein KL, Durrence HH, Riedel BW, Taylor DJ, Bush AJ,. The influence of age, gender, ethnicity, and insomnia on Epworth sleepiness scores: A normative US population. Sleep Med 2006; 7: 319-26.
138. McCord J, Mundy BJ, Hudson MP, et al. Relationship between obesity and B-type natriuretic peptide levels. Arch Intern Med 2004; 164: 2247-52.
139. Goto K, Arai M, Watanabe A, Hasegawa A, Nakano A, Kurabayashi M,. Utility of echocardiography versus BNP level for the prediction of pulmonary arterial pressure in patients with pulmonary arterial hypertension. Int Heart J 2010; 51: 343-7.
140. Logeart D, Lecuyer L, Thabut G, et al. Biomarker-based strategy for screening right ventricular dysfunction in patients with non-massive pulmonary embolism. Intensive Care Med 2007; 33: 286-92.
141. Hsich EM, Grau-Sepulveda MV, Hernandez AF, et al. Relationship between sex, ejection fraction, and B-type natriuretic peptide levels in patients hospitalized with heart failure and associations with inhospital outcomes: findings from the Get With The Guideline-Heart Failure Registry. Am Heart J 2013; 166 (1063-71): e3.
142. Krim SR, Vivo RP, Krim NR, et al. Racial/ethnic differences in B-type natriuretic Peptide levels and their association with care and outcomes among patients hospitalized with heart failure: findings from get with the guidelines-heart failure. JACC Heart Fail 2013; 1: 345-52.
143. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 2006; 47: 91-7.
144. Hess G, Runkel S, Zdunek D, Hitzler WE,. N-terminal pro-brain natriuretic peptide (NT-proBNP) in healthy blood donors and in patients from general practitioners with and without a diagnosis of cardiac disease. Clin Lab 2005; 51: 167-72.
145. Januzzi JL, van Kimmenade R, Lainchbury J, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients: The International Collaborative of NT-proBNP Study. Eur Heart J 2006; 27: 330-7.
146. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, et al. Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 2007; 167: 400-7.
147. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005; 112: 2163-8.
148. Henzler T, Roeger S, Meyer M, et al. Pulmonary embolism: CT signs and cardiac biomarkers for predicting right ventricular dysfunction. Eur Respir J 2012; 39: 919-26.
149. Li ZF, Zhou DX, Wang QB, Pan WZ, Zhang L, Ge JB,. Plasma N-terminal pro-brain natriuretic peptide levels are positively correlated with pulmonary arterial pressure in atrial septal defect patients. Regul Pept 2013; 183C: 13-6.
150. Chi SY, Kim EY, Ban HJ, et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 2012; 190: 271-6.
151. Mauritz GJ, Rizopoulos D, Groepenhoff H, et al. Usefulness of serial N-terminal pro-B-type natriuretic peptide measurements for determining prognosis in patients with pulmonary arterial hypertension. Am J Cardiol 2011; 108: 1645-50.
152. Curiati MN, Silvestre OM, Pires LJ, et al. Agreement of BNP and NT-proBNP and the influence of clinical and laboratory variables. Einstein (Sao Paulo) 2013; 11: 273-7.
153. Choi EY, Bahrami H, Wu CO, et al. N-terminal pro-B-type natriuretic peptide, left ventricular mass, and incident heart failure: Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail 2012; 5: 727-34.
154. Krauser DG, Chen AA, Tung R, Anwaruddin S, Baggish AL, Januzzi JL Jr,. Neither race nor gender influences the usefulness of amino-terminal pro-brain natriuretic peptide testing in dyspneic subjects: a ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) substudy. J Card Fail 2006; 12: 452-7.
155. Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure: the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol 2013; 168: 2186-94.
156. Stiell IG, Clement CM, Brison RJ, et al. A risk scoring system to identify emergency department patients with heart failure at high risk for serious adverse events. Acad Emerg Med 2013; 20: 17-26.
157. Peterson PN, Rumsfeld JS, Liang L, et al. A validated risk score for in-hospital mortality in patients with heart failure from the American Heart Association Get With The Guidelines Program. Circ Cardiovasc Qual Outcomes 2010; 3: 25-32.
158. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med 2008; 168: 847-54.
159. Abraham WT, Fonarow GC, Albert NM, et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J Am Coll Cardiol 2008; 52: 347-56.
160. Rohde LE, Goldraich L, Polanczyk CA, et al. A simple clinically based predictive rule for heart failure in-hospital mortality. J Card Fail 2006; 12: 587-93.
161. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ,. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 2005; 293: 572-80.